Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults

Journal of the American Geriatrics Society

Volumn 60, Issue 10, 2012, Pages 1854-1861

  Zuckerman, Ilene H ^a   Yin, Xianghua ^b   Rattinger, Gail B ^a   Gottlieb, Stephen S ^b   Simoni Wastila, Linda ^a   Pierce, Sarah A ^c   Huang, Ting Ying ^a   Shenolikar, Rahul ^d   Stuart, Bruce ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Medicare; Medicare Part D; myocardial infarction; pharmacotherapy; secondary prevention

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; COHORT ANALYSIS; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; SECONDARY PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHEMOPREVENTION; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SECONDARY PREVENTION; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84867542508     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2012.04165.x     Document Type: Article

References (44)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-2398.
3. Heidenreich PA, McClellan M,. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 2001; 110: 165-174.
4. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction: The American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005; 46: 1242-1248.
5. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. Am J Cardiol 1997; 79: 738-741.
6. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316: 1337-1343.
7. Dickstein K, Kjekshus J,. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
8. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999; 318: 1730-1737.
9. Tay EL, Chan M, Tan V, et al. Impact of combination evidence-based medical therapy on mortality following myocardial infarction in elderly patients. Am J Geriatr Cardiol 2008; 17: 21-26.
10. Setoguchi S, Glynn RJ, Avorn J, et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: A 10-year trend analysis. J Am Coll Cardiol 2008; 51: 1247-1254.
11. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons and endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: e1-e157.
12. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: e1-e211.
13. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247.
14. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366-1374.
15. Rogers AM, Ramanath VS, Grzybowski M, et al. The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: The American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J 2007; 154: 461-469.
16. Gouya G, Reichardt B, Ohrenberger G, et al. Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 2007; 22: 145-149.
17. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
18. Rasmussen JN, Chong A, Alter DA,. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-186.
19. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-461.
20. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf 2008; 17: 1189-1196.
21. Akincigil A, Bowblis JR, Levin C, et al. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008; 23: 115-121.
22. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med 2004; 117: 73-81.
23. Chang TI, Desai M, Solomon DH, et al. Kidney function and long-term medication adherence after myocardial infarction in the elderly. Clin J Am Soc Nephrol 2011; 6: 864-869.
24. Lee HY, Cooke CE, Robertson TA,. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008; 14: 271-280.
25. Jackevicius CA, Li P, Tu JV,. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117: 1028-1036.
26. Ho PM, Magid DJ, Masoudi FA, et al. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006; 6: 48.
27. Winkelmayer WC, Charytan DM, Levin R, et al. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 2006; 47: 301-308.
28. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: Frequency, predictors and associations with death and myocardial infarction-a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011; 32: 2376-2386.
29. Maio V, Marino M, Robeson M, et al. Beta-blocker initiation and adherence after hospitalization for acute myocardial infarction. Eur J Cardiovasc Prev Rehabil 2011; 18: 438-445.
30. Blackburn DF, Dobson RT, Blackburn JL, et al. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005; 25: 1035-1043.
31. Nguyen HL, Saczynski JS, Gore JM, et al. Long-term trends in short-term outcomes in acute myocardial infarction. Am J Med 2011; 124: 939-946.
32. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998; 280: 623-629.
33. Lai EJ, Grubisic M, Palepu A, et al. Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. BMC Cardiovasc Disord 2011; 11: 56.
34. Rathore SS, Mehta RH, Wang Y, et al. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003; 114: 307-315.
35. Zhu B, Zhao Z, McCollam P, et al. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin 2011; 27: 633-641.
36. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
37. Zelis R,. Calcium-blocker therapy for unstable angina pectoris. N Engl J Med 1982; 306: 926-928.
38. Spargias KS, Hall AS, Greenwood DC, et al. beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: Evidence from the AIRE study. Heart 1999; 81: 25-32.
39. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29: 229-236.
40. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574; discussion 575-577.
41. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: A proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
42. Steiner JF, Prochazka AV,. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-116.
43. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011; 365: 2088-2097.
44. Philipson TJ, Mozaffari E, Maclean JR,. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manage Care 2010; 16: 290-297.